Loading search results
GOLF
Double-blind Randomised Controlled Trial for Treatment of Gastro-Oesophageal Reflux Disease; LINX Management System vs. Fundoplication (GOLF)
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · National Institute for Health and Care Research
REGISTRY · ISRCTN: the UK's Clinical Study Registry
interventional
460
1 country
5
Study Start
March 6, 2025
Actual (reported)Primary Completion
February 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Reflux disease can severely impact upon quality-of-life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery, and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality-of-life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux symptoms. As an alternative, some surgeons use a device called LINX, using a keyhole procedure. LINX is a magnetic device that wraps around the lower oesophagus to prevent reflux. Studies suggest that LINX may cause fewer complications, with a similar improvement in quality-of-life. However, there is a need for better evidence to compare LINX with fundoplication in the surgical treatment of reflux disease. GOLF is a multi-centre study designed which to determine if LINX achieves similar reflux control and improves symptoms compared to fundoplication. GOLF measures: (1) quality of life,(2) surgical complications, including need for additional treatment, (3) financial cost-effectiveness and (4) objectively measure the presence of acid that has refluxed into the lower oesophagus. GOLF aims randomise 460 patients to receive fundoplication or the LINX device. It will be conducted across at least 16 UK and 7 European specialist surgical centres. All participants will be followed up at 6 weeks, 6, 12 and 24 months to assess which treatment offers the best results after surgery. A quality assurance programme within participating centres will ensure that procedures are completed to a high-quality standard. Study results will incorporate a patient and public involvement programme, which will inform national and international guidelines for the surgical treatment of reflux disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 6, 2025
Actual (reported)July 2, 2025
Actual (reported)July 30, 2025
Actual (reported)February 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Symptomatic GORD and health-related quality of life (HRQL) assessed using the GORD-HRQL questionnaire
24 months following surgery
Prevalence of gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
24 months postoperatively
Prevalence of inability to belch measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
24 months postoperatively
Prevalence of symptomatic GORD, inability to belch and gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
6 weeks, 6 and 12 months after surgery
Severity of dysphagia and regurgitation measured using participant-reported outcomes/GORD-HRQL questionnaire
6 weeks, 6, 12 and 24 months postoperatively
Global HRQL measured using participant-reported outcomes/EQ-5D-5L questionnaire
6 weeks, 6, 12 and 24 months postoperatively
Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.
Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.
Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.
Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.
Guy's and St Thomas's NHS Foundation Trust, Guy's and St Thomas's Hospital
Oxford, Oxfordshire, OX3 7LD, United Kingdom
Imperial College Healthcare NHS Trust, St Mary's Hospital
Oxford, Oxfordshire, OX3 7LD, United Kingdom
First Submitted
July 2, 2025
First Posted
July 30, 2025
Study Start
March 6, 2025
Actual (reported)Primary Completion
February 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Leeds Teaching Hospitals NHS Trust, St James's University Hospital
Oxford, Oxfordshire, OX3 7LD, United Kingdom
Oxford University Hospitals NHS Foundation Trust, Churchill Hospital
Oxford, Oxfordshire, OX3 7LD, United Kingdom
University Hospital Southampton NHS Foundation Trust
Oxford, Oxfordshire, OX3 7LD, United Kingdom
Study Completion
July 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 5, 2025
Record last verified: 2025-06
The data-sharing plans for the current study are unknown and will be made available at a later date.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: